Related Experiment Video
Updated: May 31, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Pim3 up-regulation by YY1 contributes to diabetes-induced cardiac hypertrophy and heart failure
Xiao-Ping Jin1,2, Yi-Fei Ren1,2, Li-Guo Wang1
1Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Objectives:
The close relationship of proto-oncogenes to myocardial hypertrophy has long been recognized, and cardiac hypertrophy leads to heart failure (HF). However, whether proviral insertion of Moloney virus 3 kinase (Pim3), a proto-oncogene, contributes to cardiac hypertrophy in diabetes mellitus (DM) remains unknown. This study aims to investigate whether Pim3 is involved in DM-induced cardiac hypertrophy and HF and to elucidate its underlying mechanisms.
Materials And Methods:
DM was induced in mice by intraperitoneal injection of streptozotocin. Cardiac function was evaluated by echocardiography, and cardiac hypertrophy was determined through histological analysis, quantitative real-time polymerase chain reaction, and western blotting. Silencing RNA transfection and lentivirus-mediated gene knockdown were performed both in vitro and in vivo. Transcriptional activity was analyzed using chromatin immunoprecipitation and luciferase reporter assay.
Results:
Compared with C57BL/6J mice, cardiac hypertrophy and dysfunction were observed in mice with DM. Pim3 mRNA and protein expression were significantly up-regulated in diabetic hearts and high glucose-cultured H9C2 cells. Yin Yang 1 (YY1), which translocated from the cytoplasm into the nucleus under hyperglycemia, bound to the Pim3 promoter and enhanced Pim3 transcriptional activity. Pim3 or YY1 knockdown profoundly reduced cell size and inhibited the mRNA and protein expression of cardiac hypertrophy markers, as well as markedly attenuating myocardial hypertrophy and cardiac dysfunction.
Conclusion:
Hyperglycemia induced nuclear translocation of YY1, leading to Pim3 up-regulation, eventually developing into cardiac hypertrophy and HF. Targeting YY1-Pim3 signaling may be a promising therapeutic avenue for DM-induced cardiac hypertrophy and HF.
Insights
Diabetes mellitus (DM) causes cardiac hypertrophy and heart failure (HF) by up-regulating proto-oncogene Pim3. Targeting the YY1-Pim3 pathway offers a potential therapy for DM-induced cardiac dysfunction.
Area of Science:
- Cardiovascular Biology
- Oncology
- Metabolic Diseases
Background:
- Proto-oncogenes are linked to myocardial hypertrophy, a precursor to heart failure (HF).
- The role of proviral insertion of Moloney virus 3 kinase (Pim3) in diabetes mellitus (DM)-induced cardiac hypertrophy is not well understood.
Purpose of the Study:
- To investigate the involvement of Pim3 in DM-induced cardiac hypertrophy and HF.
- To elucidate the molecular mechanisms underlying this process.
Main Methods:
- DM induced in mice using streptozotocin.
- Cardiac function assessed by echocardiography; hypertrophy by histology, qPCR, and Western blotting.
- In vitro and in vivo gene knockdown using siRNA and lentivirus; transcriptional activity analyzed via ChIP and luciferase assays.
Main Results:
- Diabetic mice exhibited cardiac hypertrophy and dysfunction with significantly upregulated Pim3 expression.
- Hyperglycemia induced nuclear translocation of Yin Yang 1 (YY1), which bound to the Pim3 promoter, enhancing its transcription.
- Knockdown of Pim3 or YY1 reduced cell size and cardiac hypertrophy markers, attenuating myocardial hypertrophy and dysfunction.
Conclusions:
- Hyperglycemia-induced YY1 nuclear translocation upregulates Pim3, leading to cardiac hypertrophy and HF.
- Targeting the YY1-Pim3 signaling pathway presents a potential therapeutic strategy for DM-induced cardiac hypertrophy and HF.
More Related Videos
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
11:00Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017